alexa Use of the Analgesic, Anti-inflammatory and Neuroprotectant Supplement Palmitoylethanolamide in the Tarsal Tunnel Syndrome | Open Access Journals
ISSN: 2329-910X
Clinical Research on Foot & Ankle
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Use of the Analgesic, Anti-inflammatory and Neuroprotectant Supplement Palmitoylethanolamide in the Tarsal Tunnel Syndrome

Jan M Keppel Hesselink*
Department of Molecular Pharmacology, University of Witten Herdecke, The Netherlands
Corresponding Author : Jan M Keppel Hesselink
Professor of molecular pharmacology
University of Witten Herdecke, The Netherlands
Tel: 0031-651700527
E-mail: [email protected]
Received June 18, 2015; Accepted June 20, 2015; Published June 22, 2015
Citation: Jan M. Keppel Hesselink (2015) Use of the Analgesic, Anti-inflammatory and Neuroprotectant Supplement Palmitoylethanolamide in the Tarsal Tunnel Syndrome . Clin Res Foot Ankle 3:e105. doi:10.4172/2329-910X.1000e105
Copyright: © 2015 Hesselink JMK. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at
DownloadPubmed DownloadScholar Google

Visit for more related articles at Clinical Research on Foot & Ankle

Editorial
Tarsal tunnel syndrome (TTS) is an entrapment neuropathy. Conservative treatment options include anti-inflammatory drugs not always lead to resolution, and although results of surgical decompression are good in selected patients, postoperative fibrosis can lead to recurrence of complaints. However, clinical studies in this field are pilot trials only, both for decompression techniques as well as for conservative interventions, and only few patients were evaluated in each trial. If one would select a treatment based on sufficient clinical studies, data in other compression syndromes should be considered.
We will discuss such data for palmitoylethanolamide (PEA), a natural compound available as a supplement with an excellent safety profile [1]. PEA has been studied since the 1957 of last century as an anti-inflammatory and analgesic drug in many hundreds of pharmacological studies and in more than 30 clinical trials, in a total of around 6000 patients. PEA’s efficacy and safety in nerve compression syndromes has been evaluated in nerve compression syndromes such as sciatic pain and pain due to carpal tunnel syndrome, in a total of 8 clinical trials and more than 1000 patients [2]. As the often-prescribed co-analgesic pregabalin appeared to be ineffective in a compression syndrome such as sciatic pain, PEA should be considered as an alternative treatment option for the treatment of nerve compression syndromes [3].
Nerve compression syndromes have different clinical manifestations, dependent on the localization of the compressed nerve, but they share identical pathogenesis and pain symptomatology. Research has shown that nerve pressure causes an inflammation of the nerve. Such a neuritis progresses into a more chronic pathological state due the induction of a number of cascades of chemical inflammatory reactions, and PEA can inhibit such cascades [4]. PEA is effective in various animal models of nerve compression, such as sciatic nerve ligation. PEA administered in such models decreases inflammation and pain. Repeated treatments with PEA even reduced the presence of intraneural edema and macrophage infiltrate and led to neuro-regeneration, such as a significantly thicker myelin sheath, an increased axonal diameter, and an increased number of nerve fibers [5]. These data support the use of PEA in nerve compression syndromes, and the active dose-range in most of the models was 10-30 mg/kg bodyweight. The vicious circle of inflammation, increasing pain and nerve degeneration thus can be halted by PEA.
In a double blind, placebo controlled study a high dose and a low dose of PEA was evaluated after three weeks of treatment. In this pivotal trial in six hundred and thirty-six patients suffering from pain due to radicular compression of the sciatic nerve were included. The decrease of pain was largest in the high dose group and significantly better than low dose and placebo, with more than 50% pain reduction [6]. The numbers needed to treat (NNT) of PEA at week 3 was 1.5. The number needed to harm (NNH) must be at least in the hundreds, but for the time being not calculable due to the absence of serious and troublesome side effects leading to drop-outs in clinical trials [7]. In a controlled study in 26 patients the carpal tunnel syndrome PEA reduced pain and significantly improved the compression-induced reduction of median nerve latency time [8]. In a second study in 40 patients following a group-controlled randomized design in diabetic patients suffering from carpal tunnel syndrome, with pain, PEA significantly improvement pain and all neurophysiological parameters measured improved on PEA [9].
PEA belongs to an entire new class of analgesic products, devoid of addiction potential and drug-drug interactions so far have not been documented. This co-analgesic is easy to administer (in daily dose up to 1800 mg) and is available in 400 mg capsules containing pure PEA free from excipients. The optimal dose seems 1200 mg/day. The risk-benefit balance favours its inclusion in the therapeutic armamentarium of chronic pain and in nerve compression syndromes such as the tarsal tunnel syndrome. PEA can be administered both as a standalone analgesic as well as part of a pharmacological cocktail during multi-drug therapy.
References









 

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Recommended Conferences

  • 5th International Conference on Physiotherapy
    Nov 27-28, 2017, Dubai, UAE

Article Usage

  • Total views: 11593
  • [From(publication date):
    September-2015 - Oct 20, 2017]
  • Breakdown by view type
  • HTML page views : 7857
  • PDF downloads :3736
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

environmentalsc[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords